Development of antibody-directed therapies: quo vadis?

Detalhes bibliográficos
Autor(a) principal: Rodrigues, Tiago
Data de Publicação: 2018
Outros Autores: Bernardes, Gonçalo J. L.
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: http://hdl.handle.net/10451/50253
Resumo: © 2018 The Authors. Published by Wiley-VCH Verlag GmbH & Co. KGaA. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
id RCAP_790cc740e429c960c5cf9e7cf4cf89c0
oai_identifier_str oai:repositorio.ul.pt:10451/50253
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling Development of antibody-directed therapies: quo vadis?Anti-tumor agentsAntibody-drug conjugatesBioconjugationDrug deliveryLinkers© 2018 The Authors. Published by Wiley-VCH Verlag GmbH & Co. KGaA. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.Less is more: The efficacy of antibody-drug conjugates (ADCs) for cancer therapy is traditionally associated with cleavable linkers for payload release. Evidence now suggests that simpler constructs without cleavable moieties can afford more stable and effective ADCs.We thank FCT Portugal (iFCT) the EU (Marie Sklodowska-Curie ITN ProteinConjugates) and the EPSRC to G.J.L.B. T.R. is a Marie Sklodowska-Curie Fellow (Grant 743640). G.J.L.B. is a Royal Society URF and recipient of an ERC StG (TagIt).John Wiley & Sons, Inc.Repositório da Universidade de LisboaRodrigues, TiagoBernardes, Gonçalo J. L.2021-12-02T15:42:53Z20182018-01-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10451/50253engAngew Chem Int Ed Engl. 2018 Feb 19;57(8):2032-20341433-785110.1002/anie.2017121851521-3773info:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2023-11-08T16:54:16Zoai:repositorio.ul.pt:10451/50253Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T22:01:41.967197Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv Development of antibody-directed therapies: quo vadis?
title Development of antibody-directed therapies: quo vadis?
spellingShingle Development of antibody-directed therapies: quo vadis?
Rodrigues, Tiago
Anti-tumor agents
Antibody-drug conjugates
Bioconjugation
Drug delivery
Linkers
title_short Development of antibody-directed therapies: quo vadis?
title_full Development of antibody-directed therapies: quo vadis?
title_fullStr Development of antibody-directed therapies: quo vadis?
title_full_unstemmed Development of antibody-directed therapies: quo vadis?
title_sort Development of antibody-directed therapies: quo vadis?
author Rodrigues, Tiago
author_facet Rodrigues, Tiago
Bernardes, Gonçalo J. L.
author_role author
author2 Bernardes, Gonçalo J. L.
author2_role author
dc.contributor.none.fl_str_mv Repositório da Universidade de Lisboa
dc.contributor.author.fl_str_mv Rodrigues, Tiago
Bernardes, Gonçalo J. L.
dc.subject.por.fl_str_mv Anti-tumor agents
Antibody-drug conjugates
Bioconjugation
Drug delivery
Linkers
topic Anti-tumor agents
Antibody-drug conjugates
Bioconjugation
Drug delivery
Linkers
description © 2018 The Authors. Published by Wiley-VCH Verlag GmbH & Co. KGaA. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
publishDate 2018
dc.date.none.fl_str_mv 2018
2018-01-01T00:00:00Z
2021-12-02T15:42:53Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/10451/50253
url http://hdl.handle.net/10451/50253
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv Angew Chem Int Ed Engl. 2018 Feb 19;57(8):2032-2034
1433-7851
10.1002/anie.201712185
1521-3773
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv John Wiley & Sons, Inc.
publisher.none.fl_str_mv John Wiley & Sons, Inc.
dc.source.none.fl_str_mv reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1799134565567037440

Registros relacionados